This issue of biopharmaceutical financing express covers 8 cutting-edge enterprises: Ruihe Health creates a preventive medical AI platform, Weicheng Pharmaceutical promotes extrahepatic small nucleic acid drugs, Lingke Medical focuses on sub low temperature brain protection, Tianhui Yi builds a blood purification platform, Yuanqi Biological accelerates solid tumor CAR-T clinical trials, Amet Medical lays out degradable vascular intervention devices, Haoge Rui achieves high-end CT tube localization, and Keze Yongxin breaks through the upstream raw materials of small nucleic acids. Each enterprise has obtained tens of millions to hundreds of millions of yuan in financing for technology research and development, clinical promotion, and commercial layout.

---

1、 Ruihe Health completes seed round financing to build the world’s first closed-loop platform for preventive healthcare

Recently, Ruihe Health, a preventive medical AI company, announced the completion of a seed round financing of 4 million yuan, with a post investment valuation of 25 million yuan. The investors have not yet disclosed this. This round of financing will mainly be used for clinical testing of cardiovascular and cerebrovascular disease prevention plans, medical device application, AI algorithm filing, and engineering implementation of prevention settlement closed-loop systems.

For a long time, preventive healthcare has been marginalized in the current medical payment system due to the lack of clear infrastructure support and quantitative standards for effectiveness, which seriously restricts the commercialization process of various links in the industry chain. Ruihe Health has innovatively built a four link unified platform with “prevention settlement” as its core, becoming the world’s first cross disease AI platform that directly connects prevention attribution results to payment settlement. This platform adopts medical grade federated learning technology to achieve multi-party collaborative modeling while ensuring data privacy and security. Currently, multiple patents and software copyrights have been applied for.

The Ruihe Health team chooses to focus on cardiovascular and cerebrovascular diseases, a high payout disease, to provide quantifiable prevention effect evaluation and settlement services for B-end customers such as insurance companies and physical examination centers. Its technical solution can accurately attribute the specific contribution of preventive measures to reducing the incidence of diseases, providing reliable decision-making basis for payers. At present, three medical institutions are in talks to cooperate with Ruihe Health, verifying the market’s recognition of its solutions. Ruihe Health entered the market at this time, and is expected to take the lead in establishing a commercial closed-loop of preventive medicine, laying the foundation for the subsequent replication of models to other high reimbursement diseases such as diabetes and cancer.

---

2、 Weicheng Pharmaceutical has exceeded its Series A financing of 54 million US dollars, accelerating the promotion of extrahepatic small nucleic acid therapy

Recently, Weicheng Pharmaceutical, an innovative enterprise focused on the research and development of small nucleic acid drugs targeting the liver, announced that it has exceeded its Series A financing by $54 million (approximately RMB 390 million). This round of financing is jointly led by Qiming Venture Capital and a well-known industry fund, with the participation of multiple professional investment institutions. The original investor Xingze Capital continues to increase its investment. The scale of this financing has performed outstandingly in the recent biopharmaceutical investment and financing market, fully demonstrating the high recognition of the capital market for the extrahepatic small nucleic acid therapy track and the Weicheng Pharmaceutical technology platform.

In recent years, it has shown great potential in fields such as genetic diseases and metabolic diseases. However, traditional small nucleic acid drugs mainly rely on GalNAc coupling technology to achieve liver targeting, which limits their application in extrahepatic tissue diseases. The breakthrough in extrahepatic delivery technology is driving the expansion of small nucleic acid therapy into broader fields such as neurological diseases, tumors, and ophthalmic diseases. According to industry predictions, the global market potential for extrahepatic targeted small nucleic acid drugs is expected to exceed billions of dollars in the next decade.

Since its establishment in 2025, Weicheng Pharmaceutical has focused on the bottleneck of extrahepatic delivery technology and built a delivery platform with significant differentiation advantages. Its core technology is expected to solve the common industry problems of poor targeting and low delivery efficiency of small nucleic acid drugs in extrahepatic tissues, providing key technical support for expanding the indications of small nucleic acid drugs.

It is reported that the funds raised in this round of financing will mainly be used for three core directions: continuous iteration and optimization of the technology platform, preclinical promotion and application preparation of existing pipelines, and expansion of the R&D team and establishment of a global R&D network. The founder of Weicheng Pharmaceutical stated that the company will take advantage of this financing opportunity to accelerate the pace of platform technology verification and pipeline development, and focus on promoting several internationally competitive extrahepatic targeted small nucleic acid projects to enter the clinical stage. The core team of Weicheng Pharmaceutical has rich experience in the research and industrialization of small nucleic acid drugs. Its differentiated technical route and clear clinical development strategy give it a first mover advantage in the emerging field of extrahepatic small nucleic acid therapy. The successful completion of this financing will provide a solid guarantee for the company to promote technological platform iteration and pipeline development.

---

3、 Lingke Medical has completed a Pre-A round of financing worth tens of millions of yuan, focusing on expanding its ultra-low temperature brain protection technology

Recently, Lingke Medical Technology (Hangzhou) Co., Ltd. announced the completion of tens of millions of yuan in Pre-A round financing, which is exclusively invested by the Brain Science Fund under Delian Capital.

As a leading domestic enterprise specializing in hypothermia brain protection technology, Lingke Medical is committed to providing innovative solutions for ischemic stroke patients through intelligent and precise temperature control treatment technology, and promoting the localization process of domestic high-end medical devices. Ischemic stroke is one of the most deadly and disabling diseases in China, and neuroprotective strategies are particularly crucial in clinical treatment.

Low temperature therapy is widely recognized as an effective neuroprotective measure, which can significantly reduce brain metabolic rate and alleviate reperfusion injury. However, traditional techniques suffer from pain points such as inaccurate temperature control and complex operation. Lingke Medical has built a product matrix covering intravascular heat exchange systems and non-invasive surface temperature control systems based on clinical needs, achieving a comprehensive layout from invasive to non-invasive scenarios. Its system achieves precise temperature control of ± 0.1 ℃ level through intelligent algorithms, which has significant advantages in safety, stability, and automation. The core competitiveness of Lingke Medical is not only reflected in technological barriers, but also stems from its “medical engineering integration” research and development model. The team is composed of clinical medical experts and senior engineering technicians, who can quickly respond to clinical feedback and promote continuous product iteration.

At present, the company has cooperated with multiple tertiary hospitals to promote product clinical validation and data accumulation, laying the foundation for subsequent medical device registration applications. According to the founder, this round of financing will mainly be used for the refined research and development of precision temperature control technology platforms, increasing investment in core algorithms and hardware systems, and accelerating the construction of multi center clinical research and commercial channels. The goal of Lingke Medical is to gradually break the long-term monopoly of overseas brands in the field of neuroprotective temperature control equipment through technological breakthroughs and product implementation. The head of Delian Capital pointed out that Lingke Medical has demonstrated strong technological depth and clinical adaptability in the field of precise temperature management, and is expected to become a leading enterprise in the domestic neuroprotection and emergency temperature control treatment direction. With the standardization of stroke treatment and the popularization of emergency thrombolysis and thrombectomy techniques, precise temperature control, as an important auxiliary treatment method, is rapidly releasing its market potential.

---

4、 Ningbo Tianhui Yi has completed a financing of over 100 million yuan, accelerating the construction of a blood purification platform

On April 10th, Ningbo Tianhuiyi Medical Technology Co., Ltd. (hereinafter referred to as “Tianhuiyi”) announced the completion of a new round of financing exceeding 100 million yuan. This round of financing is led by Fuzhe Fund, followed by Yongshan Fund, and old shareholder Hongsheng Capital continues to increase its investment. This is the second significant financing completed by the company within a year, following the tens of millions of yuan raised in June of the previous year, fully demonstrating the high recognition of the capital market for its strategic layout and growth potential. This round of funding will focus on the integration and operation of Bellco’s blood purification assets, as well as the registration and commercialization of core products.

Tianhui Yi has previously successfully integrated Nikkiso’s CRRT (Continuous Renal Replacement Therapy) business. The acquisition of Bellco will further complete its product matrix in the field of blood purification, covering multi scenario treatment needs from acute and severe to chronic disease management. This layout not only strengthens Tianhui Yi’s advantages in the CRRT field, but also extends its business to a full range of product lines such as hemodialysis and plasma exchange, laying a solid foundation for building a comprehensive blood purification platform.

The successful completion of two consecutive rounds of financing marks Tianhui Yi’s transition from a single product operator to a new stage of platform based development. By integrating high-quality international assets through mergers and acquisitions, Tianhui Yi is rapidly building a full industry chain capability with independent intellectual property rights and technological competitiveness. Against the backdrop of policies promoting domestic substitution and new medical infrastructure, its platform based strategy is expected to seize the dividends of the rapid growth of the blood purification market and seize the industry’s high ground.

---

5、 Yuanqi Biotechnology completes $110 million Pre IPO round financing to accelerate global development of solid tumor CAR-T technology

Recently, clinical biotechnology company Yuanqi Biotechnology announced the completion of a Pre IPO round of financing totaling $110 million (approximately RMB 800 million). This round of financing is led by Weiwu Capital and jointly participated by multiple well-known investment institutions. The financing funds will mainly be used to promote the global multi center clinical research of the company’s core product pipeline and further expand its international business layout. This financing not only marks a key progress for Yuanqi Biotechnology in the capital market, but also lays a solid foundation for its IPO impact.

The breakthrough of the core pipeline is imminent, and Ori-C101 is expected to fill the gap in the treatment of hepatocellular carcinoma. Ori-C101 (also known as OriCAR-017), the core candidate drug of Genshin Impact, focuses on the treatment of advanced hepatocellular carcinoma (HCC) and has shown significant clinical potential. If the subsequent clinical trials proceed smoothly, this product is expected to become the world’s first CAR-T cell therapy drug approved for marketing for hepatocellular carcinoma, providing new hope for advanced patients who lack effective treatment methods. Hepatocellular carcinoma, as a highly prevalent malignant tumor worldwide, has limited existing therapies. The research and development progress of Ori-C101 has attracted industry attention, and its breakthrough will have important clinical and market value.

In addition to its core products, Yuanqi Biotechnology has continuously incubated multiple next-generation CAR-T products with its independently innovated technology platform, covering more indications for solid tumors and hematological tumors. Its technological strength has been validated in the development process of Ori-C101, especially in target screening, T cell expansion, and tumor microenvironment regulation, where it has differentiated advantages. The company adopts a development strategy of “platform incubation pipeline”, aiming to build a product matrix with sustainable innovation capabilities and inject momentum into long-term growth. **Capital is optimistic about internationalization strategy and accelerating the promotion of global multi center clinical trials

This round of financing has received support from multiple first-line investment institutions such as Weiwu Capital, reflecting the recognition of the capital market for the technological strength and commercialization prospects of Yuanqi Biotechnology. After the financing, the chairman of the company stated that it will concentrate resources to promote global clinical research of core pipelines, accelerate the construction of international teams and the registration and application process.

---

6、 The first domestic carbon dioxide contrast injection device has been approved, and Amet Medical has completed over 200 million rounds of D-round financing technology

Recently, Beijing Amet Medical Equipment Co., Ltd. (hereinafter referred to as “Amet”) announced the completion of a Series D financing of over 200 million yuan, led by Zhejiang Sheng Collaborative Life and Health Fund. After the investment, the company’s valuation has exceeded 1.5 billion yuan. It is reported that the funds raised in this round will mainly be used for the research and registration certification of 3D printed biodegradable vascular stents, as well as the market promotion of China’s first carbon dioxide contrast injection device.

With the continuous expansion of the number of cardiovascular disease patients in China, the demand for pan vascular intervention diagnosis and treatment has significantly increased, and the advanced treatment concept of “intervention without implantation” is increasingly recognized in clinical practice. Amet Medical, with its forward-looking strategic layout, has successfully developed multiple biodegradable stents and supporting interventional products. Currently, it has obtained 5 medical device registration certificates and its product line covers important areas such as coronary arteries and peripheral blood vessels. It is worth noting that the independently developed carbon dioxide contrast injection device by Amet has become the first product in China, effectively solving the contraindications of traditional iodine contrast agents for patients with renal insufficiency, allergic constitution, and other conditions, and providing a safe and reliable alternative to contrast for special populations. This product has not only received a prepayment of tens of millions from domestic distributors, but has also successfully obtained EU CE certification and US FDA certification, achieving commercialization in overseas markets and demonstrating strong international competitiveness.

Amet’s core competitiveness lies in its independently built 3D multi axis precision manufacturing technology platform. This platform not only enables high-precision and high-efficiency medical device manufacturing, but also helps the company complete the core patent layout from research and development to manufacturing, building a solid technological moat. The investment institution’s heavy bet this time is precisely because they are optimistic about Amet’s sustained technological innovation capabilities and the global business potential of its products.The founder of the company stated that after this round of financing, it will accelerate the entry of core products into key hospitals in China, and through deepening clinical cooperation, create a technological and academic highland in the field of degradable vascular intervention. With the deepening of product commercialization, Amet is expected to occupy an important position in the wave of domestic substitution and overseas expansion of high-end medical devices.

---

7、 Haoge Rui has completed a strategic financing of tens of millions of yuan, and domestic football tubes have landed in multiple tertiary hospitals

Recently, domestic high-end medical imaging core component manufacturer, Haoge Rui Technology, announced the completion of a strategic round of financing worth tens of millions of yuan, with multiple industry partners participating in the investment. It is reported that this round of funds will mainly be used for the large-scale production of ball tube products, research and development of next-generation technologies, and market expansion. Previously, the company had received early support from multiple leading investment institutions, with a cumulative financing scale approaching 100 million yuan.

Haoge Rui Technology is one of the few innovative enterprises in China that has mastered the core technology of “high-power liquid metal bearing tube”. Its independently developed SpaceSpin liquid metal bearing technology has achieved important breakthroughs in key indicators such as thermal capacity management, speed stability, and service life, successfully overcoming the bottleneck that has long restricted the performance improvement of domestic CT equipment. The company’s first high-end CT tube product Primus40Plus has officially obtained the medical device registration certificate issued by the National Medical Products Administration (NMPA), and has successfully entered several well-known tertiary hospitals in China for installation and application, marking that domestic tubes have the strength to replace imports in terms of reliability and image quality.
Industry analysis points out that as the core component with the highest technical barrier and the largest cost proportion in CT equipment, the localization process of CT tube has been relatively lagging behind. The technological breakthroughs of Haoge Rui not only help reduce the equipment procurement and maintenance costs of domestic medical institutions, but also have strategic significance for enhancing the independent and controllable capabilities of China’s high-end medical equipment industry chain. After this round of financing, Haoge Rui will focus on promoting the mass delivery of existing products and capacity construction, consolidating its first mover advantage in the domestic tube field.

---

8、 Keze Yongxin, a small nucleic acid upstream raw material enterprise, has completed tens of millions of yuan in Pre-A round financing

Recently, there have been heavy financing news in the upstream raw material field of small nucleic acid drugs in China. Shanghai Keze Yongxin Biotechnology Co., Ltd. (hereinafter referred to as “Keze Yongxin”) has completed a Pre-A round financing of tens of millions of RMB. This round of financing is led by Disheng Capital, with the original investor Jiale Capital continuing to make additional investments. It is reported that the funds raised in this round will mainly be used for the large-scale construction of the production base of the Anhui subsidiary, further expanding the production capacity of high-quality raw materials.

Keze Yongxin was founded in 2023. Although it is a rising star in the industry, it has been awarded the title of “High tech Enterprise” in a short period of time due to the profound technical accumulation of its core doctoral entrepreneurial team, and has successfully built an industry-leading technology platform. The company focuses on the research and production of key raw materials and enzyme preparations required for the production of small nucleic acid drugs, aiming to break through the bottleneck links in the upstream supply chain. Its product quality benchmarks international standards and is committed to providing stable and reliable supply chain support for the growing domestic small nucleic acid drug research and development enterprises.

For this investment, the project leader of leading investor Di Sheng Capital stated: “Small nucleic acid drugs, as cutting-edge therapies, have shown great potential in the treatment of genetic diseases, metabolic diseases, and other fields. The global market is on the eve of an outbreak. We highly value China’s development prospects in this field, and a stable upstream raw material supply chain is the cornerstone of the entire industry’s rise. The Keze Yongxin team has demonstrated outstanding technological advantages and the ultimate pursuit of quality, and is expected to become a leading enterprise in the domestic small nucleic acid raw material field. The successful completion of this financing indicates that the capital market continues to be optimistic about the value of the small nucleic acid golden track and its key upstream links. The next step of Keze Yongxin’s development is worth looking forward to in the industry.

---

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: info@meritsip.com

© 2025 MeritsIP. All Rights Reserved.